bms-984923
Small moleculeexperimental
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 25, 2021 (NCT04805983)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
GRIK1 modulator
Chemistry & pharmacology
Loading structure…
SMILES
O=C1N[C@H](c2cncc(C#Cc3ccccc3)c2)[C@@H](c2ccccc2Cl)O1- Mol. weight
- 374.83 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4571075 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06632990 | Phase 1 | Nov 30, 2024 | Allyx Therapeutics, National Institute on Aging (NIA) |
| NCT06309147 | Phase 1 | Mar 15, 2024 | Allyx Therapeutics, Duke University, Michael J. Fox Foundation for Parkinson's Research |
| NCT05804383 | Phase 1 | Mar 28, 2023 | Allyx Therapeutics, National Institute on Aging (NIA), Yale University |
| NCT05817643 | Phase 1 | Jan 10, 2023 | Allyx Therapeutics, Michael J. Fox Foundation for Parkinson's Research |
| NCT04805983 | Phase 1 | Mar 25, 2021 | National Institute on Aging (NIA), Yale University |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Allyx Therapeutics | For profit | 4 | 4 | 1 | 2023 |
| National Institute on Aging (NIA) | Government | 3 | 0 | 1 | 2021 |
| Michael J. Fox Foundation for Parkinson's Research | Academic/Hospital | 2 | 0 | 1 | 2023 |
| Yale University | Academic/Hospital | 2 | 1 | 1 | 2021 |
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2024 |
5 organizations
Page 1 / 1